Fig. 4From: Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from GermanyAbsolute standardized mean differences for baseline variables before and after propensity score matching. MHD: monthly headache days. Broken line marks a standardized mean difference of 0.1Back to article page